Published on 24/12/2025
A Comparative Guide to ANDA in the U.S. and Generic Applications in the EU
Introduction: Global Generic Drug Market and Regulatory Pathways
Generic drugs account for over 80% of prescriptions filled in the United States and a significant portion of medicines dispensed across the European Union (EU). Despite a shared objective—to provide safe, effective, and lower-cost alternatives to brand-name drugs—the regulatory pathways for generic drug approval in the U.S. and EU vary substantially.
The U.S. system relies on the Abbreviated New Drug Application (ANDA) pathway regulated by the FDA, while the EU offers multiple procedures (national, decentralized, mutual recognition, and centralized) regulated by the European Medicines Agency (EMA) and national authorities.
Regulatory Authorities and Governing Legislation
In the U.S., the Food and Drug Administration (FDA) oversees the review and approval of generic drugs under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The key guiding legislation is the Hatch-Waxman Act.
- U.S. Authority: Center for Drug Evaluation and Research (CDER), FDA
- EU Authorities: EMA and National Competent Authorities (NCAs)
Application Formats: ANDA vs Generic CTD
Both regions use the Common Technical Document (CTD) structure but with regional variations:
| Module | Content | U.S. ANDA | EU Generic Application |
|---|---|---|---|
| 1 | Administrative and Regional | FDA-specific forms (e.g., 356h) | EMA/NCA forms; RMS/CMS info |
| 2 | Overviews and Summaries | Required | Required |
| 3 | Quality (CMC) | Same CTD format | Same CTD format |
| 4 | Nonclinical | Not required for ANDA | Waived unless justified |
| 5 | Clinical and BE | In vivo or in vitro BE studies | Bioequivalence or literature |
Submission Processes, Bioequivalence, Timelines, and Regional Nuances
Submission and Review Processes
In the U.S., ANDA submissions are made electronically via the Electronic Submissions Gateway (ESG) and reviewed by the Office of Generic Drugs (OGD).
In the EU, applicants can choose among:
- National Procedure (NP): Approval in one Member State only
- Decentralized Procedure (DCP): Simultaneous approval in several countries using a Reference Member State (RMS)
- Mutual Recognition Procedure (MRP): Extension of an existing national approval to additional countries
- Centralized Procedure (CP): Single approval valid across all EU Member States (mandatory for some drug types)
EU applications are managed via systems like the Common European Submission Portal (CESP) and Clinical Trials Information System (CTIS) for trial-related components.
Bioequivalence (BE) Requirements: Similar but Not Identical
Bioequivalence studies are central to both ANDA and EU generic submissions, but key differences exist:
- U.S.: Single-dose, crossover study in healthy volunteers with fasting and sometimes fed conditions. 90% CI of 80–125% for AUC and Cmax.
- EU: BE studies must align with the EMA’s “Guideline on the Investigation of Bioequivalence,” which includes statistical rigor and sometimes replicate designs for highly variable drugs.
- Biowaivers: Both regions accept BCS-based waivers, with the EU allowing them for Class I and III drugs under specific conditions.
EU applications often include a justification of BE based on literature or foreign approvals in lieu of full clinical data.
Timelines and Review Duration
| Region | Standard Review Time | Expedited Pathway |
|---|---|---|
| U.S. (ANDA) | 10 months (GDUFA) | Priority Review (8 months) |
| EU (DCP) | 210 days + clock stops | No formal accelerated route for generics |
While the FDA provides predictable timelines under GDUFA, EU reviews vary depending on the number of Concerned Member States (CMS) and the complexity of the dossier.
Data Exclusivity and Market Protection
- U.S.: New drugs get 5 years data exclusivity; generics must wait. First-filers may get 180-day exclusivity.
- EU: Data exclusivity lasts 8 years, plus 2 years market exclusivity and an optional 1-year extension (“8+2+1” rule).
This can delay generic entry in the EU even if the brand product is no longer patent-protected.
Real-World Example: Generic Approval of Atorvastatin
In the U.S., atorvastatin (Lipitor) generic approval followed the ANDA pathway with a first-filer enjoying 180-day exclusivity. In the EU, multiple companies pursued DCP submissions with mutual recognition across several Member States.
Both regions required robust bioequivalence data, but submission and review strategies differed significantly, especially in how market access was granted.
Post-Approval Changes and Variations
U.S.: Changes are classified as Prior Approval Supplements (PAS), Changes Being Effected (CBE-0, CBE-30), or Annual Reports.
EU: Variation procedures are categorized as Type IA, IB, or II under Commission Regulation (EC) No 1234/2008.
EU changes must often be coordinated across Member States, adding complexity for multinational generic sponsors.
Conclusion: Strategic Planning Is Key in Both Markets
While both the U.S. and EU aim to ensure safety, efficacy, and quality of generic drugs, the regulatory approaches differ in structure, timeline, and regional complexity. Understanding these differences helps sponsors design efficient submission strategies tailored to each market.
Sponsors aiming for global reach should invest in harmonizing their CTD dossiers, building region-specific regulatory intelligence, and proactively managing timelines to ensure synchronized launches across major territories.